CRF Bracket announced the launch of a new Planning module added within SmartSupplies. Offering simplicity, visualization and control to life science companies, this module makes SmartSupplies the only fully integrated, 21 CRF Part 11compliant solution that enables closed-loop conduct of clinical supply forecasting, planning and inventory management.
The SmartSupplies Planning module will modernize how life science companies generate clinical supply manufacturing plans, replacing cumbersome, tedious spreadsheets. It dynamically graphs clinical supply and demand at the project and program levels using real-time forecast data pulled in directly from the SmartSupplies Forecasting module or from any other external sources such as simulation tools and spreadsheets.
Using the Smart Supplies Planning, Forecasting, and Inventory Management as a completely integrated solution produces a comprehensive end-to-end solution that digitally controls, tracks and traces the entire clinical supply chain. The Planning Module can also be used as a standalone solution to collate and visualize disparate sources of imported demand to enable aggregated supply and asset planning.
“Clinical supply chains can be complex to manage due to variability that results from protocol changes, undefined doses, unexpected recruitment rates, batch failures and non-availability of raw materials, among other challenges,” says Oliver Cunningham, Senior Director of Client Enablement, SmartSupplies, CRF Bracket.“SmartSupplies changes that-it’s purpose-built to fully digitize the entire clinical supply chain. By integratingforecasting, planning and inventory managementthe system enables on-demand lot recall and offers full traceability.”
The SmartSupplies Forecasting & Planning solutions will help sponsors reduce the effort required to build forecasts, make better manufacturing decisions, and reduce supply overages and associated costs. Companies like AstraZenecahave already made the enterprise-wide switch from Excel to SmartSupplies, saving 10% of their clinical supply budget, representing millions of US dollars annually, through better forecasting. The addition of the SmartSupplies Planning model will further increase the visibility of all supply chain activities and allow the system to optimize manufacturing plans thereby lowing the risk of stockouts or overproduction of investigational medicinal product.
To learn more about SmartSupplies Forecasting & Planning and SmartSupplies Inventory Management, visit http://pages.crfhealth.com/SmartSupplies_Forecasting_Planning.html
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.